We are delighted to welcome you to join us for this virtual meeting:
UK real world experience with MAYZENT▼ (siponimod) in SPMS patients with active disease
19th October 2021
MAYZENT▼ is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
This promotional meeting intended for UK HCPs is organised and funded by Novartis Pharmaceuticals UK Ltd.
UK | October 2021 | 157857
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard.
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at email@example.com